Management of medication overuse headache
BMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c1305 (Published 28 April 2010) Cite this as: BMJ 2010;340:c1305
- Drug and Therapeutics Bulletin
- 1Drug and Therapeutics Bulletin Editorial Office, London WC1H 9JR
- dtb{at}bmjgroup.com
Headache is one of the most frequent reasons for medical consultation in both general practice and specialist neurology clinics.1 Prescribed and over-the-counter medications are taken to alleviate headaches, but may be used incorrectly.2 In particular, use of some drugs both frequently and regularly can have a paradoxical effect, causing headaches rather than relieving them, and leading to medication overuse headache (MOH).3 Such overuse is a common cause of frequent headache. Here we review MOH and its management.
About MOH
The International Classification of Headache Disorders, 2nd edition states that for a diagnosis of MOH, all of the following criteria must be present:
headache occurring on 15 or more days per month;
regular overuse for more than 3 months of one or more acute/symptomatic treatment drugs (ergotamine, triptans, opioids or combined analgesic medications [typically simple analgesics plus opioids or caffeine] on 10 or more days per month; or simple analgesics alone or any combination of ergotamine, triptans and analgesic opioids on 15 or more days per month); and
development or marked worsening of headache during medication overuse.4
The preceding headache problem
Headaches may be primary (eg, migraine, tension-type headache, cluster headache) or secondary (eg, associated with trauma, subarachnoid haemorrhage, intracranial neoplasm, infection or the use or withdrawal of substances such as alcohol or drugs).3 5 MOH occurs only in patients with a history of primary headache.6 7 It is most likely to affect patients with migraine and/or tension-type headache,7 8 but can also arise in association with cluster headache, particularly if there is a personal or family history of migraine or regular headache.9
Epidemiology
Studies from various countries suggest that the prevalence of MOH is around 1% of adults and 0.5% of adolescents (aged 13–18 years) in the general population;10 around 25–64% in those attending tertiary care headache …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.